Drug updated on 3/28/2024
| Dosage Form | Injection (intramuscular; 50 mcg/0.5 mL) |
| Drug Class | Vaccines |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For prevention of herpes zoster (HZ) (shingles): in adults aged 50 years and older, and in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.
Summary
- Zoster vaccine recombinant, adjuvanted (Shingrix) is indicated for the prevention of herpes zoster (HZ), also known as shingles, in adults aged 50 years and older or those at increased risk due to immunodeficiency or immunosuppression caused by disease or therapy.
- Two systematic reviews/meta-analyses were reviewed that provided information on Shingrix's effectiveness against HZ and its complications.
- The first meta-analysis found that vaccination with Shingrix was associated with a lower risk of stroke compared to unvaccinated patients, suggesting it may have additional benefits beyond preventing HZ infection.
- However, this study did not find any association between antiviral treatment and reduced stroke risk after HZ infection indicating that preventive measures like vaccination might be more effective than post-infection treatments.
- The second review evaluated the effectiveness of two types of herpes zoster vaccines: recombinant zoster vaccine [RZV] (Shingrix) and zoster vaccine live [ZVL]. It concluded both RZV and ZVL are effective in preventing herpes zoster in routine clinical practice but noted substantial heterogeneity among studies included in their analysis.
- This review also highlighted the efficacy of these vaccines across various comorbidities including diabetes, chronic kidney disease, liver disease heart disease,and lung diseases which suggests broad applicability for diverse patient populations.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Shingrix (zoster vaccine recombinant, adjuvanted) Prescribing Information. | 2023 | GlaxoSmithKline Durham, NC |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Effects of herpes zoster vaccination and antiviral treatment on the risk of stroke: a systematic review and meta-analysis. | 2023 | Frontiers in Neurology |
| Post-licensure zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in older adults: a systematic review and meta-analysis. | 2022 | The Lancet Healthy Longevity |